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Abstract
Background: While studies of HIV-infected adults on antiretroviral treatment (ART) report no sex differences in
immune recovery and virologic response but more ART-associated complications in women, sex differences in
disease progression and response to ART among children have not been well assessed. The objective of this study
was to evaluate for sex differences in response to ART in South African HIV-infected children who were randomized
to continue ritonavir-boosted lopinavir (LPV/r)-based ART or switch to nevirapine-based ART.
Methods: ART outcomes in HIV-infected boys and girls in Johannesburg, South Africa from 2005–2010 were
compared. Children initiated ritonavir-boosted lopinavir (LPV/r)-based ART before 24 months of age and were
randomized to remain on LPV/r or switch to nevirapine-based ART after achieving viral suppression. Children were
followed for 76 weeks post-randomization and then long-term follow up continued for a minimum of 99 weeks and
maximum of 245 weeks after randomization. Viral load, CD4 count, lipids, anthropometrics, drug concentrations, and
adherence were measured at regular intervals. Outcomes were compared between sexes within treatment strata.
Results: A total of 323 children (median age 8.8 months, IQR 5.1-13.5), including 168 boys and 155 girls, initiated
LPV/r-based ART and 195 children were randomized. No sex differences in risk of virological failure (confirmed
viral load >1000 copies/mL) by 156 weeks post-randomization were observed within either treatment group.
Girls switched to nevirapine had more robust CD4 count improvement relative to boys in this group through
112 weeks post-randomization. In addition, girls remaining on LPV/r had higher plasma concentrations of ritonavir
than boys during post-randomization visits. After a mean of 3.4 years post-randomization, girls remaining on
LPV/r also had a higher total cholesterol:HDL ratio and lower mean HDL than boys on LPV/r.
Conclusions: Sex differences are noted in treated HIV-infected children even at a young age, and appear to
depend on treatment regimen. Future studies are warranted to determine biological mechanisms and clinical
significance of these differences.
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Background
Studies of sex differences in the course of HIV infection
in adults report lower HIV-1 RNA levels and higher
CD4 counts in women compared to men, but similar
disease progression and clinical outcomes between sexes
[1,2]. Responses to antiretroviral treatment (ART), in-
cluding immune reconstitution and virologic response,
are also similar [3,4]. However, ART-associated compli-
cations, including hepatotoxicity, pancreatitis, as well as
metabolic abnormalities and lipodystrophy are consist-
ently reported more often in women than men [5-11].
The differential effects in ART response between sexes
appear to be driven by sex-specific physiological and
hormonal influences as well as by differences in drug
pharmacokinetics [12,13]. Social and behavioral factors
may also play a role, as rates of adherence and treatment
discontinuation vary between men and women [14].
Less is known about sex differences in disease progres-
sion and response to ART among children. Differences in
CD4 count and HIV-1 RNA between boys and girls have
been reported in treatment-naïve HIV-infected children
[15]. In treated children, one study reported lower HIV-1
RNA in girls than boys and no differences in CD4 count
[16] while two observational studies reported a more rapid
immunologic response to ART in girls [17,18]. Sex differ-
ences in incidence of ART-associated complications re-
ported in children [19-23] have rarely been assessed.
A better understanding of sex differences in the pathobi-
ology of HIV and its complications would be aided by
evaluation of these differences during early childhood
when biologic, social, and behavioral differences are less
pronounced than in adulthood. The objective of this study
was to evaluate for sex differences in response to ART in
South African HIV-infected children who were random-
ized to continue ritonavir-boosted lopinavir (LPV/r)-based
ART or switch to nevirapine-based ART.
Methods
Study design
In order to assess for sex differences in immunologic, vi-
rologic, anthropometric, and other responses to anti-
retroviral regimens, we performed a secondary analysis
of data collected as part of Neverest 2, a clinical trial
(ClinicalTrials.gov: NCT00117728) assessing the reuse of
nevirapine in nevirapine-exposed HIV-infected children
conducted from 2005 to 2010 [24,25]. Children previ-
ously exposed to single-dose nevirapine prophylaxis at
birth, and <24 months of age at the time of initiation of
LPV/r-based ART, were identified at Rahima Moosa
Mother and Child Hospital in Johannesburg, South Africa.
Those who achieved and sustained plasma HIV-1 RNA
<400 copies/mL for ≥3 months during the first 12 months
of treatment were eligible for randomization to either con-
tinue on LPV/r or switch to nevirapine-based ART in
combination with stavudine and lamivudine. Specific
treatment regimens have been previously reported [24,25].
Children were followed for 76 weeks post-randomization
and then re-enrolled in extended follow up. In this ana-
lysis, we evaluated sex differences pretreatment, in the
pre-randomization phase, at the time of randomization, at
post-randomization study visits, and at participants’ final
visit. This study was approved by the Institutional Review
Boards of Columbia University (New York, New York)
and the University of the Witwatersrand (Johannesburg,
South Africa). Informed consent was provided by each
child’s parent or guardian.
Measurements
Socio-demographic information, medical history, weight
(kg), height (cm), and blood samples (for CD4 T-cell de-
termination and HIV-1 RNA quantity) were collected at
a pretreatment visit. Subsequent visits were scheduled at
2, 4, 8, 12, and every 12 weeks thereafter up to 52 weeks
until randomization and at 2, 4, 8, 16, 24, 36, 52, 64, 76
and every 12 weeks thereafter. Blood samples for plasma
viral load tests by quantitative HIV-1 RNA PCR (Roche,
Cobas Ampliprep Taqman V2, Branchburg, NJ) were
collected at 4, 16, 24, 36, 52, 64, and 76 weeks post-
randomization and for absolute CD4 count and percent-
ages (Beckman Coulter Flow Analyzer) at 16, 24, 36, 52,
64, and 76 weeks post-randomization, and for both tests
at every 12 weeks thereafter until the final study visit.
Lopinavir, ritonavir, and nevirapine plasma concentrations
were determined using validated LC-MS/MS assays devel-
oped in the Division of Clinical Pharmacology, Cape
Town, South Africa. An AB Sciex 4000 mass spectrometer
was operated at unit resolution in the multiple reaction
monitoring mode. The assays were validated over the con-
centration range of 0.16-20 μg/ml for lopinavir, 0.10-
20 μg/ml for nevirapine, and 0.04-5 μg/ml for ritonavir.
Non-fasting total cholesterol, low-density lipoprotein
(LDL), high-density lipoprotein (HDL), and triglycerides
in mg/dL were measured at pretreatment, time of
randomization, and 36, 88, and 136 weeks post
randomization (Roche, Cobas Integra 400, Branchburg,
NJ). At the final study visit following an overnight fast,
total cholesterol, LDL, HDL, triglycerides, C-reactive
protein in mg/L, and insulin in mg/dL were measured.
Venous blood glucose in mg/dL was measured with a
handheld glucometer and homeostasis model assessment
of insulin resistance (HOMA-IR) was calculated [26].
Classification of biochemical results has been described
previously [22]. Assessments for drug-related rashes and
hepatotoxicity by alanine aminotransferase (ALT) were
performed at post-randomization visits [24,25].
Weight (kg) and height (cm) were measured using a
digital scale and stadiometer, respectively. Weight-for-
age (WAZ) and height-for-age z-scores (HAZ) were
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calculated using World Health Organization growth
standards [27]. Underweight was defined as WAZ < −2
and stunting was defined as HAZ < −2. Circumferences
at the mid-upper arm, mid-upper thigh, mid-waist, and
maximum hip were measured using a flexible tape meas-
ure with a spring tension attachment. Bicep, tricep, sub-
scapular, suprailiac, umbilical, and mid-thigh skinfolds
were measured with a Harpendon caliper (Baty Inter-
national, England). As previously reported, total body fat
percent (%BF) was estimated by single-frequency bioimpe-
dance analysis (BIA) (Quantum II, RJL Systems, Clinton
Township, MI) [28] and children were classified as hav-
ing lipodystrophy, possible lipodystrophy, or no signs of
lipodystrophy by two physicians (RS, LM) [22].
All children with HIV-1 RNA >1000 copies/mL were
recalled and retested within 4 weeks. Additional coun-
seling was provided if adherence difficulties were de-
tected. Children in the switch group were returned to
the LPV/r-based regimen if HIV-1 RNA remained >1000
copies/mL despite enhanced adherence counseling. To
evaluate adherence, caregivers were asked to return drug
at all scheduled visits. Percentage of medication return
was calculated and poor adherence was defined as 20%
greater than expected medication return for each drug.
Statistical analysis
All outcomes were compared between sexes within
treatment strata as well as between treatment groups
within sex strata. Intent-to-treat comparisons were
made for treatment groups. Kaplan-Meier methods and
log-rank tests were used to describe time to virologic
failure. For comparisons between groups at specific
time points, we used the Wilcoxon rank-sum test for
non-normally distributed continuous variables, t-test
for normally-distributed continuous variables, and Chi-
square or Fisher exact tests for categorical variables.
Generalized estimating equation models were used to
compare outcomes with repeated measurements over
time using a first order autoregressive correlation struc-
ture, adjusting for baseline differences. Tests for inter-
action between sex and treatment group were performed.
All p-values are 2-tailed and p-values <0.05 were consid-
ered statistically significant. Analyses were performed
using SAS version 9.1.3 (Cary, North Carolina, USA).
Results
Study population
The flow of participants is shown in Figure 1. A total of
323 HIV-infected children, including 168 (52%) boys, were
enrolled in the study and initiated LPV/r-based ART. In
the period between initiating LPV/r-based treatment and
randomization to either remain on LPV/r or switch to ne-
virapine (pre-randomization phase), 38 (11.8%) died, 40
(12.4%) did not remain in follow up, and 50 (15.5%) did
not meet criteria for randomization. Of the 195 children
randomized in the study, 99 remained on LPV/r, including
Figure 1 Flow diagram of study participants in Neverest 2. Flow diagram of study participants in Neverest 2; Abbreviations: LPV/r, lopinavir-
boosted ritonavir; NVP, nevirapine; ART, antiretroviral therapy; LTFU, lost to follow up; B, boys; G, girls.
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50 (50.5%) boys, and 96 were switched to nevirapine,
including 54 (56.3%) boys. Children were followed for
76 weeks post-randomization during which time four
(2.1%) children died and 15 (7.7%) children were lost to
follow up. Long-term follow up continued for a mini-
mum of 99 weeks and maximum of 245 weeks after
randomization. At study completion in June 2010, six
(3.1%) children died, 28 (14.4%) were lost to follow-up,
and five (2.6%) transferred out. 156 (80%) completed
the final study visit.
Pretreatment characteristics
The pretreatment characteristics of the 323 children
initiating LPV/r-based ART are presented in Table 1.
Overall, more boys initiated ART after 6 months of age
(p = 0.009). Boys also had a lower mean WAZ and
HAZ and a greater proportion of boys were under-
weight and stunted. The pretreatment anthropometric
differences remained after adjusting for age at treat-
ment initiation. No differences between sexes were seen
in other pretreatment characteristics. In the pre-
randomization period, similar proportions of boys and
girls died, were lost to follow up, or did not meet cri-
teria for randomization (data not shown). Results were
similar if only the 195 children randomized were ana-
lyzed, but the mean WAZ of boys and the proportion
of boys underweight and stunted were no longer sig-
nificantly different than girls.
Viral load
There were no differences between boys and girls in
either the proportion who attained viral load suppres-
sion to <400 copies/mL by 6 months into the pre-
randomization phase (78.9 vs. 76.9%, p = 0.747), or the
proportion with viral load <50 copies/mL at randomization
(61.5 vs. 64.8%, p = 0.634) when all children were on
Table 1 Pretreatment characteristics of 323 perinatally HIV-infected South African children enrolled in Neverest 2
by sex
Characteristics Enrolled children (n = 323)
Boys (n = 168) Girls (n = 155) P-value
Age at treatment start, N (%)
<6 months 41 (24.4) 61 (39.4)
6-12 months 70 (41.7) 45 (29.0) 0.009
12-24 months 57 (33.9) 49 (31.6)
Median (range) in months 9.6 (2.2-24.2) 7.9 (2.0-24.9) 0.098
HIV-1 RNA quantity, N (%) 0.475
<100,000 copies/ml 16 (10.6) 9 (6.8)
100,000-750,000 copies/ml 39 (25.8) 39 (29.6)
≥750,000 copies/ml 96 (63.6) 84 (63.6)
CD4 count in cells/mm3, Mean (SD) 1001 (724) 1011 (786) 0.909
CD4 percent, N (%)
<10 30 (19.1) 25 (17.0)
10-14.9 35 (22.3) 26 (17.7) 0.463
≥15 92 (58.6) 96 (65.3)
Median (range) 16.8 (0.8-43.0) 19.1 (1.2-39.1) 0.163
WHO Stage, N (%)
I/II 29 (21.0) 22 (17.5) 0.465
III/IV 109 (79.0) 104 (82.5)
Weight for age Z-score
Mean (SD) −2.70 (1.8) −2.28 (1.6) 0.041
Z-score < −2, N (%) 98 (66.7) 71 (49.7) 0.003
Height for age Z-score
Mean (SD) −3.72 (1.8) −3.11 (1.6) 0.003
Z-score < −2, N (%) 125 (86.2) 108 (76.6) 0.037
Note: Categorical variables were compared across groups using X2 tests; median age, CD4 percentage, and time on therapy were compared using Wilcoxon tests;
CD4 count and height and weight for age z-scores were compared using t-tests. Denominators are as shown.
Abbreviations: LPV/r Lopinavir-boosted ritonavir, NVP Nevirapine, ART Antiretroviral therapy, LTFU Lost to follow up.
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LPV/r. The probability of virologic failure (confirmed
viral load >1000 copies/mL) by 52 weeks post-
randomization was similar between boys and girls who
remained on LPV/r (0 vs. 0.043, p = 0.162) as well as
between boys and girls who switched to nevirapine
(0.224 vs. 0.172, p = 0.575). The probability of virologic
failure by 156 weeks was also similar between boys and
girls who remained on LPV/r (0.115 vs. 0.104, p = 0.996)
as well as between boys and girls who switched to nevi-
rapine (0.240 vs. 0.238, p = 0.954). Proportions of boys
and girls in viremia categories (<50, 50–1000, >1000
copies/mL) within treatment groups were similar at all
scheduled post-randomization visits.
CD4 percentage and count
While the mean CD4 percentage and cell count in-
creased in the pre-randomization phase for boys and
girls in both treatment groups, differences in CD4 re-
sponse between sexes were noted among those switched
to nevirapine post-randomization. Girls who switched to
nevirapine had a more robust CD4 count response than
boys switched to nevirapine from 24 weeks up to
112 weeks post randomization (on average CD4 count
306 cells/μL higher, p = 0.045), with significantly higher
mean CD4 cell counts at 24, 64, and 100 weeks post-
randomization (p = 0.027, 0.036, 0.043 respectively) and
higher CD4 percentage at 64, 76, and 100 weeks post-
randomization (p = 0.028, 0.035, 0.047, respectively)
(Figure 2). After adjustment for age at ART initiation,
pretreatment WAZ, HAZ, and CD4 count, on average
CD4 count remained significantly higher for girls than
boys from 24 to 112 weeks after randomization to nevi-
rapine (p = 0.0089). The observed differences were no
longer detectable at 148 weeks.
Metabolic and laboratory assessments
No significant differences in mean total cholesterol,
LDL, HDL, and triglycerides were found pretreatment,
at randomization, or at scheduled visits 36, 88, and
136 weeks post-randomization between boys and girls
(data not shown) [23]. Upon exit from the study, girls
continuing on LPV/r had a higher total cholesterol:HDL
ratio and lower mean HDL concentration than boys on
LPV/r, as well as compared to girls on nevirapine (3.8 vs.
3.0, p = 0.002 and 48 vs. 57 mg/dL, p = 0.007, respect-
ively), and girls on LPV/r had a higher mean HOMA-IR
than boys on LPV/r (Table 2). There were no differences
in proportions of boys and girls within treatment groups
with drug related rashes or Grade 3 or 4 ALT at any
scheduled post-randomization visits (data not shown).
Anthropometrics
WAZ for boys and girls increased rapidly in the pre-
randomization phase (Figure 2); the mean change in
WAZ for boys was greater than girls, though not signifi-
cant (1.69 vs. 1.50, p = 0.386). After randomization, boys
A C
B D
Figure 2 Immunologic and anthropometric outcomes over time. Mean CD4 percent (A) and CD4 count (B), weight-for-age z-score (WAZ)
(C) and height-for-age z-score (HAZ) (D) before treatment, at randomization, and at scheduled visits with measurements through 148 weeks after
randomization in Neverest 2 by sex and randomization group; Abbreviations: WAZ, weight-for-age z-score; HAZ, height-for-age z-score; LPV/r,
lopinavir-boosted ritonavir; NVP, nevirapine.
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on LPV/r consistently had a lower WAZ than boys on
nevirapine through 148 weeks, but this difference was
not statistically significant. There were no sex differences
in likelihood of dropping more than one Z score in
WAZ before 52 weeks post-randomization.
Mean change in HAZ was greater for girls than boys in
the pre-randomization phase when all children were on
LPV/r, though this difference was not significant (0.14
vs. -0.06, p = 0.473). After randomization, height for
boys and girls on both treatment regimens improved
through 148 weeks (Figure 2). Mean HAZ was significantly
lower for boys than girls on nevirapine at randomization
(−3.38 vs. -2.99, p = 0.021). HAZ stayed lower for boys on
nevirapine than girls on nevirapine through 52 weeks
post-randomization (b = −0.57, p = 0.031). The associ-
ation remained when adjusted for age at initiation of
ART (b = −0.54, p = 0.026), but not when adjusted for
pretreatment HAZ (b = −0.38, p = 0.145).
At the final study visit, girls had a larger %BF by BIA
than boys (18.7 vs. 12.8%, p < 0.0001). A similar pattern
was observed by cumulative skinfold sum, though this dif-
ference was not significant (42.9 vs. 39.7 mm, p = 0.076).
Patterns of fat were similar between boys and girls in both
treatment randomization groups (Table 3). There were no
differences in proportions of children with lipodystrophy
between boys and girls.
Drug concentrations and adherence
Of those randomized to remain on LPV/r, the plasma
concentrations of ritonavir adjusted for WAZ and time
since dose was on average 0.115 μg/ml higher in girls
than boys (p = 0.048) in scheduled post-randomization
visits. No significant sex differences in lopinavir concen-
trations were observed. Of those switched to nevirapine,
there were no sex differences in nevirapine concentra-
tions. There were no differences between boys and girls
Table 2 Metabolic and other laboratory assessments of 156 perinatally HIV-infected South African children at the final
study visit of Neverest 2 by sex within treatment randomization group
Measurement LPV/r (n = 85) NVP (n = 71)
Boys (n = 41) Girls (n = 44) P-value Boys (n = 40) Girls (n = 31) P-value
Total Cholesterol, mg/dL Mean (SD) 170 (39) 172 (39) 0.816 163 (25) 159 (38) 0.533
Acceptable: <170
N (%)
24 (58.5) 21 (47.7) 0.603 29 (72.5) 23 (74.2) 0.884
Borderline: 170-199 10 (24.4) 14 (31.8) 8 (20.0) 5 (16.1)
Elevated: ≥200 7 (17.1) 9 (20.5) 3 (7.5) 3 (9.7)
HDL, mg/dL Mean (SD) 54 (14) 48 (12) 0.044 60 (15) 57 (16) 0.352
Abnormal: <35 N (%) 2 (4.9) 5 (11.4) 0.277 0 (0.0) 2 (6.4) 0.103
Normal: ≥35 39 (95.1) 39 (88.6) 40 (100.0) 29 (93.6)
LDL, mg/dL Mean (SD) 98 (31) 101 (38) 0.664 89 (24) 87 (29) 0.738
Acceptable: <110 N (%) 28 (68.3) 28 (63.6) 0.895 31 (77.5) 25 (80.7) 0.516
Borderline: 110-129 7 (17.1) 9 (20.5) 7 (17.5) 3 (9.7)
Elevated: ≥130 6 (14.6) 7 (15.9) 2 (0.5) 3 (9.7)
Total Cholesterol: HDL Ratio Mean (SD) 3.3 (1.0) 3.8 (1.1) 0.049 2.8 (0.7) 3.0 (1.0) 0.547
Triglycerides, mg/dL Mean (SD) 88 (34) 99 (42) 0.207 69 (27) 74 (32) 0.457
Normal: ≤150 N (%) 37 (90.2) 37 (84.1) 0.398 39 (97.5) 30 (96.8) 0.855
Abnormal: >150 4 (9.8) 7 (15.9) 1 (2.5) 1 (3.2)
C-Reactive Protein, mg/L Mean (SD) 3.2 (5.6) 3.8 (6.5) 0.453 9.5 (23.8) 9.8 (18.1) 0.423
Normal: ≤3 N (%) 33 (80.5) 36 (81.8) 0.875 27 (67.5) 19 (61.3) 0.587
Elevated: >3 8 (19.5) 8 (18.2) 13 (32.5) 12 (38.7)
Glucose, mg/dL Mean (SD) 96.9 (7.1) 96.4 (7.8) 0.736 97.6 (9.2) 93.7 (8.5) 0.070
Normal: <110 N (%) 80 (98.8) 41 (100.0) 0.332 74 (98.7) 39 (97.5) 0.375
Impaired: ≥110 1 (1.2) 0 (0.0) 1 (1.3) 1 (2.5)
HOMA-IR Mean (SD) 0.90 (0.5) 1.16 (0.6) 0.036 1.17 (1.0) 0.96 (0.6) 0.289
Normal: ≤3.16 N (%) 41 (100.0) 44 (100.0) 1.0 36 (92.3) 31 (100.0) 0.115
Resistance: >3.16 0 (0.0) 0 (0.0) 3 (7.7) 0 (0.0)
Abbreviations: LPV/r Lopinavir-boosted ritonavir, NVP Nevirapine, HDL High-density lipoprotein, LDL Low-density lipoprotein, HOMA-IR Homeostatic model
assessment of insulin resistance.
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in the proportion of children non-adherent to their
drugs at any post-randomization scheduled visits as
assessed by medication return percentages.
Discussion
In this randomized clinical trial, we assessed sex differ-
ences in treatment outcomes of South African HIV-
infected children initiated on LPV/r before age two and
later randomized to remain on LPV/r or switch to nevi-
rapine after attaining suppression of viremia. Though no
sex differences were observed in virologic response, girls
switched to nevirapine had a more robust immunologic
response than boys switched to nevirapine. In addition,
after a minimum of 99 and maximum of 245 weeks on
ART, girls on LPV/r had a higher total cholesterol:HDL
ratio and lower mean HDL concentration than boys on
LPV/r. As children remain on life-long treatment, these
sex disparities noted early in life may have implications
for long term clinical outcomes.
Few pediatric studies have assessed sex differences in
virologic response to ART. Similar to a recent meta-
analysis of virologic outcomes in treatment-experienced
adults [3] and a randomized trial comparing nevirapine
and LPV/r-based treatment initiation in young children
with no prior nevirapine exposure [29], our study ob-
served no sex differences in suppression of virus in
response to ART. This finding is in contrast to an earlier
study in children on mono- or dual-nucleoside analogue
therapy that reported lower viral load levels in girls than
boys [16].
Our finding that girls switched to nevirapine have a
greater immunologic response than boys is similar to re-
sults from two observational studies conducted in chil-
dren receiving non-nucleoside reverse transcriptase
inhibitors (NNRTI)-based regimens [17,18]. A stronger
CD4 cell count response in women, compared to men
after treatment initiation, has also been reported in a
large cohort study of HIV-infected adults, the majority
of whom were initiated on NNRTI-based therapy [30],
but these results appear to be explained by higher base-
line CD4 count in women. In contrast, our association
remained when adjusted for pretreatment CD4 count as
well as age at ART initiation. The reason for the differ-
ence in CD4 response by sex among children randomly
assigned to switch to nevirapine is unclear, but it does
not appear to be due to better drug adherence or viral
suppression or differences in drug concentrations; the
difference may reflect underlying sex differences in CD4
parameters that have been reported in healthy unin-
fected children [31]. The consequences of this time-
limited difference are also unclear. High baseline CD4
cell count has been identified as a risk factor for
Table 3 Body composition measures of 156 perinatally HIV-infected South African children at the final study visit of
Neverest 2 by sex within treatment randomization group, Mean (SD)
Measurement LPV/r (n = 85) NVP (n = 71)
Boys (n = 41) Girls (n = 44) P-value Boys (n = 40) Girls (n = 31) P-value
MUAC, cm 16.1 (15.2) 15.5 (2.0) 0.288 15.2 (1.8) 15.1 (2.1) 0.844
MWC: MHC Ratio 1.25 (1.9) 0.93 (0.1) 0.287 0.95 (0.1) 0.95 (0.1) 0.773
SFS, mm 41.9 (12.1) 44.0 (10.1) 0.408 37.2 (9.7) 41.3 (10.3) 0.120
%BF by BIA 14.5 (6.2) 19.2 (7.0) 0.002 10.9 (7.6) 17.9 (6.9) 0.0002
Extremity Fat Area
Arm Fat Area, cm2 5.52 (2.0) 6.05 (2.2) 0.259 4.91 (1.3) 5.65 (2.0) 0.063
% of Fat in Arm 26.6 (5.5) 31.5 (9.6) 0.006 27.2 (8.2) 30.9 (8.2) 0.063
Leg Fat Area, cm2 14.9 (5.5) 16.5 (6.5) 0.236 12.3 (4.4) 15.2 (6.1) 0.025
% of Fat in Leg 20.1 (5.6) 23.4 (7.4) 0.028 17.7 (4.5) 21.6 (6.4) 0.006
Regional Fat Proportion of Total Body Fat
Arm: [(BSF + TSF)/SFS] 0.30 (0.05) 0.30 (0.04) 0.985 0.31 (0.05) 0.29 (0.03) 0.197
Trunk: [(SSF + SISF + USF)/SFS] 0.46 (0.07) 0.45 (0.06) 0.484 0.47 (0.05) 0.47 (0.05) 0.658
Leg: [MTSF/SFS] 0.24 (0.04) 0.25 (0.04) 0.297 0.22 (0.03) 0.24 (0.04) 0.026
Trunk-Extremity Skinfold Ratios
Trunk-Arm: [(SSF + SISF)/(BSF + TSF + SSF + SISF)] 0.49 (0.06) 0.50 (0.06) 0.652 0.50 (0.04) 0.51 (0.06) 0.306
Trunk-Leg: [(SSF + SISF)/(MTSF + SSF + SISF)] 0.55 (0.06) 0.55 (0.07) 0.978 0.58 (0.04) 0.57 (0.06) 0.278
Abbreviations: LPV/r Lopinavir-boosted ritonavir, NVP Nevirapine, MUAC Mid-upper arm circumference, MWC Mid-waist circumference, MHC Maximum hip
circumference, BSF Bicep skinfold, TSF Tricep skinfold, SSF Subscapular skinfold, SISF Suprailiac skinfold, USF Umbilical skinfold, MTSF Mid-thigh skinfold,
SFS Skinfold sum, %BF Percent body fat, BIA Bioimpedance analysis.
Note: Cumulative skinfold sum (SFS) was calculated by adding BSF, TSF, SSF, SISF, USF, and MTSF. Extremity fat areas, regional fat proportions of total body fat,
and trunk-extremity skinfold ratios were calculated as previously reported [22].
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nevirapine-related hepatotoxicity during ART initiation in
women and pregnant women [32], but we did not see in-
creased abnormal ALT levels or drug-related rashes in girls
on nevirapine. Although it is unclear if the incremental in-
crease in CD4 response we observed among girls switched
to nevirapine will have long term benefits, the simultan-
eous rapid improvement in growth suggests that there is a
clinical benefit for these girls during this time period.
Although studies in adults observe more lipid abnor-
malities in ART-treated women [11,33-36], to our know-
ledge, no prior studies have reported sex differences in
metabolic outcomes in children. The differences we ob-
serve do not appear to be explained by underlying sex
differences in healthy children [37,38] and may be a re-
sult of greater exposure to ritonavir in girls. Ritonavir is
known to adversely affect lipid metabolism through sup-
pression of the degradation of the nuclear form of sterol
regulatory element binding proteins in the liver and
other sites, resulting in increased fatty acid and choles-
terol production [39]. Higher ritonavir drug concentra-
tion have been previously reported in adult women [40],
and may be driven by sex differences in body size and
composition as well as drug metabolism, transport, and
excretion [13].
Sex differences in growth parameters during ART were
also detected. Though height remained significantly
lower for boys on nevirapine than girls on nevirapine up
to 52 weeks post-randomization after adjusting for age
at initiation of ART, it was no longer significant when
adjusted for pretreatment height. We have previously re-
ported that earlier age of ART initiation can affect
growth [41]. Few studies have compared growth re-
sponses between sexes; one study of older children re-
ported higher rates of stunting in boys than girls [42]. In
our study, we noted higher levels of fat in girls than boys
which may reflect underlying sex differences in total
body fat observed in healthy children [43-45]. Greater
fat accumulation in girls, as reported in studies of older
HIV-infected children during puberty, may be related to
estrogen effects on fat accumulation [46,47]. In the present
study in which all children were pre-pubertal, however, we
did not observe sex differences in prevalence of lipohyper-
trophy or other forms of lipodystrophy [46,48].
Although our study is one of the first to evaluate sex
differences in childhood response to potent combination
ART, it has limitations. Children in this trial met eligibil-
ity criteria for treatment based on South African guide-
lines in place at the time and only those who attained viral
suppression in the first year of therapy were randomized
[49]. Thus, our study has limited generalizability to popu-
lations with suboptimal adherence or virologic response.
In addition, we were not able to assess the potential rela-
tionship between drug pharmacokinetics and body com-
position, or detect rare adverse events.
Conclusions
In this study, we observed no sex differences in viral
suppression; however, compared to boys switched to ne-
virapine, girls switched to nevirapine had a more robust
immune recovery. In addition, girls on LPV/r had a
more unfavorable lipid profile compared to boys on
LPV/r at the final study visit. This study provides a
glimpse into early childhood sex differences related to
ART. The course and long term consequences of these
differences with respect to immunologic and metabolic
outcomes is unknown. Future studies of sex differences
among HIV-infected children should focus on pharmaco-
kinetics as well as pathophysiologic pathways including
chronic inflammation, immune senescence and mitochon-
drial dysfunction which may influence the therapeutic re-
sponse and risk of complications. The potential effects of
factors such as malnutrition, infections, co-morbidity, viral
sub-type, and underlying genetic profiles also warrant fur-
ther investigation during childhood and adolescence.
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